https://orcid.org/0000-0002-7217-7900
References
- MitryMA, EdwardsJG. Doxorubicin induced heart failure: phenotype and molecular mechanisms. IJC Hear Vasc. 2016;10:17–24. doi:10.1016/j.ijcha.2015.11.004
- BarpeDR, RosaDD, FroehlichPE. Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. Eur J Pharm Sci. 2010;41(3–4):458–463. doi:10.1016/j.ejps.2010.07.01520688160
- SchauppCM, WhiteCC, MerrillGF, KavanaghTJ. Metabolism of doxorubicin to the cardiotoxic metabolite doxorubicinol is increased in a mouse model of chronic glutathione deficiency: a potential role for carbonyl reductase 3. Chem Biol Interact. 2015;234:154–161. doi:10.1016/j.cbi.2014.11.01025446851
- KatzungBG, MastersSB, TrevorAJ. Basic & Clinical Pharmacology. 12th ed. McGraw Hill; 2012.
- TaoJJ, VisvanathanK, WolffAC. Long term side effects of adjuvant chemotherapy in patients with early breast cancer. The Breast. 2015;24:S149–53. doi:10.1016/j.breast.2015.07.03526299406
- LuuAZ, ChowdhuryB, Al-OmranM, TeohH, HessDA, VermaS Role of endothelium in doxorubicin-induced cardiomyopathy. JACC Basic to Transl Sci. 2018;(6):861–870 doi:10.1016/j.jacbts.2018.06.005
- Drug BC. Doxorubicin; 2010; 5(March):1–10. Available from: http://www.bccancer.bc.ca/drug-database-site/DrugIndex/Doxorubicin_monograph.pdf. Accessed 84, 2020.
- ZengX, CaiH, YangJ, QiuH, ChengY, LiuM. Pharmacokinetics and cardiotoxicity of doxorubicin and its secondary alcohol metabolite in rats. Biomed Pharmacother. 2019;116(April):108964. doi:10.1016/j.biopha.2019.10896431102935
- AhmedS, KishikawaN, OhyamaK, WadaM, NakashimaK, KurodaN. Selective determination of doxorubicin and doxorubicinol in rat plasma by HPLC with photosensitization reaction followed by chemiluminescence detection. Talanta. 2009;78(1):94–100. doi:10.1016/j.talanta.2008.10.04319174209
- Sakai-KatoK, SaitoE, IshikuraK, KawanishiT. Analysis of intracellular doxorubicin and its metabolites by ultra-high-performance liquid chromatography. J Chromatogr B Anal Technol Biomed Life Sci. 2010;878(19):1466–1470. doi:10.1016/j.jchromb.2010.03.040
- EMEA. Guideline on bioanalytical method validation. EMEA/CHMP/EWP/192217/2009 Rev 1 Corr 2** [Internet]; 2011; 44(July 2011):1–23. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf. Accessed 84, 2020.
- FDA. Bioanalytical Method Validation Guidance. Cder; 5 2018:25.
- MarshS, LiuG. Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy. Adv Drug Deliv Rev. 2009;61(5):381–387. doi:10.1016/j.addr.2008.10.00319100797
- LalS, SandanarajE, WongZW, et al. CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci. 2008;99(10):2045–2054. doi:10.1111/j.1349-7006.2008.00903.x19016765
- MostellerRD. Simplified calculation of body-surface area. N Engl J Med. 1987;317(17):1098. doi:10.1056/NEJM1987102231717173657876